Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72787
Title:
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Authors:
Ferraldeschi, Roberta; Thatcher, Nick; Lorigan, Paul C ( 0000-0002-8875-2164 )
Abstract:
Pemetrexed is a novel, multitargeted antifolate currently under development for the treatment of a number of solid tumors, including small-cell lung cancer. Pemetrexed/platinum combinations appear to compare favorably with other platinum-based doublets in terms of their efficacy and safety profile. The Global Analysis of Pemetrexed in SCLC Extensive Stage (GALES) trial is a direct comparison of pemetrexed and carboplatin with the standard first-line etoposide and carboplatin chemotherapy in extensive-disease small-cell lung cancer. This randomized, multicenter, open-label Phase III study will enroll 1820 patients in 23 countries, with the final analysis planned after 1270 deaths have occurred. An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. roberta_ferraldeschi@yahoo.com
Citation:
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. 2007, 7 (5):635-40 Expert Rev Anticancer Ther
Journal:
Expert Review of Anticancer Therapy
Issue Date:
May-2007
URI:
http://hdl.handle.net/10541/72787
DOI:
10.1586/14737140.7.5.635
PubMed ID:
17492928
Type:
Article
Language:
en
ISSN:
1744-8328
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFerraldeschi, Roberta-
dc.contributor.authorThatcher, Nick-
dc.contributor.authorLorigan, Paul C-
dc.date.accessioned2009-07-07T15:06:39Z-
dc.date.available2009-07-07T15:06:39Z-
dc.date.issued2007-05-
dc.identifier.citationPemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. 2007, 7 (5):635-40 Expert Rev Anticancer Theren
dc.identifier.issn1744-8328-
dc.identifier.pmid17492928-
dc.identifier.doi10.1586/14737140.7.5.635-
dc.identifier.urihttp://hdl.handle.net/10541/72787-
dc.description.abstractPemetrexed is a novel, multitargeted antifolate currently under development for the treatment of a number of solid tumors, including small-cell lung cancer. Pemetrexed/platinum combinations appear to compare favorably with other platinum-based doublets in terms of their efficacy and safety profile. The Global Analysis of Pemetrexed in SCLC Extensive Stage (GALES) trial is a direct comparison of pemetrexed and carboplatin with the standard first-line etoposide and carboplatin chemotherapy in extensive-disease small-cell lung cancer. This randomized, multicenter, open-label Phase III study will enroll 1820 patients in 23 countries, with the final analysis planned after 1270 deaths have occurred. An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshEtoposide-
dc.subject.meshGlutamates-
dc.subject.meshGuanine-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMesothelioma-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.titlePemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. roberta_ferraldeschi@yahoo.comen
dc.identifier.journalExpert Review of Anticancer Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.